NCT06757153View on ClinicalTrials.gov

Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 19, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

December 31, 2027

Conditions
Glioblastoma (GBM)
Interventions
DRUG

NRG-103

NRG-103 is an oncolytic virus, which can kill GBM cells via three manners.

Trial Locations (1)

430000

RECRUITING

Zhongnan Hospital of Wuhan University, Wuhan

All Listed Sponsors
lead

Zhongnan Hospital

OTHER